Rhapsody Biologics Secures Exclusive License From Exploit Technologies To Create A Unique And Versatile Personalised Peptide Vaccine (PPV) Platform  
3/3/2010 12:59:30 PM

Exploit-Tech -- Singapore, 2 March 2010 – Rhapsody Biologics (S) Pte Ltd, a Singapore start-up, had on 2 March 2010 licensed from Exploit Technologies a portfolio of technologies that has gone into the creation a versatile Personalised Peptide Vaccine (PPV) platform to predict and optimise peptide vaccines for use at an individual and population level. The portfolio of technologies is developed by Prof Ren Ee Chee at the Singapore Immunology Network (SIgN) of the Singapore Agency for Science, Technology and Research (A*STAR).